These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 15635690)
1. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen. Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690 [TBL] [Abstract][Full Text] [Related]
2. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study. Grinstead JS; Schuman JT; Campbell AP Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698 [TBL] [Abstract][Full Text] [Related]
3. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762 [TBL] [Abstract][Full Text] [Related]
5. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat. Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048 [TBL] [Abstract][Full Text] [Related]
6. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and antibody recognition of synthetic antigens from MUC1. Bánóczi Z; Mezõ G; Windberg E; Uray K; Majer Z; Hudecz F J Pept Sci; 2008 May; 14(5):610-6. PubMed ID: 17975847 [TBL] [Abstract][Full Text] [Related]
9. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576 [TBL] [Abstract][Full Text] [Related]
10. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Kam JL; Regimbald LH; Hilgers JH; Hoffman P; Krantz MJ; Longenecker BM; Hugh JC Cancer Res; 1998 Dec; 58(23):5577-81. PubMed ID: 9850097 [TBL] [Abstract][Full Text] [Related]
11. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Karsten U; Serttas N; Paulsen H; Danielczyk A; Goletz S Glycobiology; 2004 Aug; 14(8):681-92. PubMed ID: 15115750 [TBL] [Abstract][Full Text] [Related]
12. Binding of tumor antigen mucin (MUC1) derived peptides to the heat shock protein DnaK. Schreiber J; Stahn R; Schenk JA; Karsten U; Pecher G Anticancer Res; 2000; 20(5A):3093-8. PubMed ID: 11062727 [TBL] [Abstract][Full Text] [Related]
13. Design of a MUC1-based cancer vaccine. Hanisch FG Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pepscan analyses for epitope mapping of anti-MUC1 monoclonal antibodies--a comparative study and review of five antibodies. Petrakou E; Murray A; Rosamund C; Graves L; Price MR Anticancer Res; 1998; 18(6A):4419-21. PubMed ID: 9891503 [TBL] [Abstract][Full Text] [Related]
15. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. von Mensdorff-Pouilly S; Kinarsky L; Engelmann K; Baldus SE; Verheijen RH; Hollingsworth MA; Pisarev V; Sherman S; Hanisch FG Glycobiology; 2005 Aug; 15(8):735-46. PubMed ID: 15814824 [TBL] [Abstract][Full Text] [Related]
16. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894 [TBL] [Abstract][Full Text] [Related]
19. Functional neoglycopeptides: synthesis and characterization of a new class of MUC1 glycoprotein models having core 2-based O-glycan and complex-type N-glycan chains. Matsushita T; Sadamoto R; Ohyabu N; Nakata H; Fumoto M; Fujitani N; Takegawa Y; Sakamoto T; Kurogochi M; Hinou H; Shimizu H; Ito T; Naruchi K; Togame H; Takemoto H; Kondo H; Nishimura S Biochemistry; 2009 Nov; 48(46):11117-33. PubMed ID: 19852465 [TBL] [Abstract][Full Text] [Related]
20. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]